Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Lucas F, Mata DA, Greenblatt MB, Means J, Jarolim P. A Potassium-Based Quality-of-Service Metric Reduces Phlebotomy Errors, Resulting in Improved Patient Safety and Decreased Cost. Am J Clin Pathol. 2022;157(5):789-798.

Xiang G, Wang S, Chen L, Song M, Song X, Wang H, et al. UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer. Cell Death Dis. 2022;13(5):451.

Man L, Guahmich NL, Kallinos E, Caiazza B, Khan M, Liu Z-, et al. Chronic superphysiologic AMH promotes premature luteinization of antral follicles in human ovarian xenografts. Sci Adv. 2022;8(10):eabi7315.

Domingues V, Chock EY, Dufrost V, Risse J, Seshan SV, Barbhaiya M, et al. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev. 2022;21(10):103158.

Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, et al. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. J Clin Oncol. 2022;40(35):4119-4128.

Panarelli NC. In Reply. Arch Pathol Lab Med. 2022;146(10):1182a-1182.

Cai PY, Asad M, Augello MA, Martin L, Louie C, Basourakos SP, et al. A multidisciplinary approach to optimize primary prostate cancer biobanking. Urol Oncol. 2022;40(6):271.e1-271.e7.

Cayrol F, Revuelta MV, Debernardi M, Paulazo A, Phillip JM, Zamponi N, et al. Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. Mol Cancer Ther. 2022;21(9):1485-1496.

Shouval R, Fein JA, Cho C, Avecilla ST, Ruiz J, Tomas AA, et al. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv. 2022;6(5):1525-1535.

Francini E, Fanelli GN, Pederzoli F, Spisak S, Minonne E, Raffo M, et al. Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine. Cancers (Basel). 2022;14(18).